The KC increase was significantly lower in the treated groups compared to the BD group: Coversin group FC 2.8 (1.0-4.5) (p = 0.009), anti-CD14 group FC 0.9 (0.5–1.4) (p < 0.0001) and the dual treatment group FC 2.5 (-0.8-5.9 (p = 0.002) (Fig. 4C). This evidence concerns the gene CALCA and Behcet disease.